Spectinomycin 2g powder and solvent for suspension for injection vials
Requires a prescription from a doctor or prescriber
An antibiotic produced by Streptomyces spectabilis.
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Yellow Card
Report side effects (MHRA)
Drug safety updates
MHRA alerts for Spectinomycin
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Suspected adverse reactions reported for Spectinomycin
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
View EudraVigilance report
Suspected adverse reactions reported for Spectinomycin
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
1 branded products available
MHRA licensed products
View all licensed products for Spectinomycin on the MHRA register
Trobicin 2g powder and solvent for suspension for injection vials
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Reviews & meta-analyses: 1 · 1965–2026
Showing the 50 most relevant studies, sorted by most relevant.
Vougat Ngom R, Ferreira HCC, Ayissi G, et al.
2025
- Chickens
- Escherichia coli Infections
- Poultry Diseases
The aim of this study was to evaluate, through a systematic review and meta-analysis, the efficacy of antibiotics in controlling colibacillosis in broiler production, by synthesizing evidence from randomized controlled trials (RCTs). The Cochrane method and the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines were followed, and the databases CAB abstract, Agricola, PubMed and Web of Science were searched using relevant keywords to identify studies. Eligible studies had to report at least one of the following outcomes: mortality, feed conversion ratio (FCR), condemnations at slaughter and total antibiotic use. Risk of bias (RoB) by outcome of individual study and pairwise meta-analysis by outcome and antibiotic or antibiotics combination, when at least three studies were available, were also conducted. Out of 24,778 articles found in the searched databases, 48 studies were eventually selected. Most of the studies reported mortality as outcome (n = 43) and tested the antibiotic as metaphylactic treatment (n = 41). A total of 47 antibiotics belonging to 18 different classes were tested in the selected studies with enrofloxacin as the most studied. The overall RoB was "some concerns" in 78.2% of studies for mortality outcome and 73.7% for FCR outcome. Meta-analysis showed that doxycycline (0.04; 95% CI 0.02-0.10; P < 0.001) had the highest protective effect against mortality due to colibacillosis, followed by spectinomycin (0.11; 95% CI 0.05-0.26; P < 0.001), enrofloxacin (0.12; 95% CI 0.06-0.25; P < 0.001), lincomycin plus spectinomycin (0.22; 95% CI 0.13-0.38; P < 0.001), flumequine (0.25; 95% CI 0.14-0.44; P < 0.001) and oxytetracycline (0.31; 95% CI 0.20-0.50; P < 0.001). However, these results should be interpreted with caution due to the low number of studies included in the meta-analysis and the high variability in the animal models and study designs across RCTs. This review underscores the necessity for continued research to refine treatment strategies of colibacillosis in broiler production in line with the evolving regulatory and public health guidelines related to antibiotic use in animals.
Abstract licence: CC BY
N. Clark, Ø. Olsvik, J. Swenson, et al.
Antimicrobial Agents and Chemotherapy, 1999
- Amino Acid Sequence
- Base Sequence
- Drug Resistance, Microbial
Susan K. Hollingshead, Daniel Vapnek
Plasmid, 1985
- Genes, Bacterial
- R Factors
- Amino Acid Sequence
J. Donald, Leblanc, Linda N. Lee, et al.
Antimicrobial Agents and Chemotherapy, 1991
- Spectinomycin
- Base Sequence
- Cloning, Molecular
M.A. Borovinskaya, Shinichiro Shoji, James M. Holton, et al.
ACS Chemical Biology, 2007
- Spectinomycin
- Anti-Bacterial Agents
- Escherichia coli
Patrick Trieu-Cuot, C. Carlier, C. Poyart-Salmeron, et al.
Nucleic acids research, 1990
- Genetic Vectors
- Spectinomycin
- Cloning, Molecular
John W. Boslego, Edmund C. Tramont, Ernest T. Takafuji, et al.
New England Journal of Medicine, 1987
- Spectinomycin
- Drug Resistance, Microbial
- Gonorrhea
Heriberto Cerutti, Anita Johnson, Nicholas W. Gillham, et al.
Genetics, 1997
- Genes, Bacterial
- Transformation, Bacterial
- Gene Expression
Alex Bollen, J. Davies, M. Ozaki, et al.
Science, 1969
Ellen Murphy
Molecular and General Genetics MGG, 1985
- Genes
- Genes, Bacterial
- Spectinomycin
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Approved
Major interactions
None known
Half-life
1 to 3 hours
Mechanism
Spectinomycin is an inhibitor of protein synthesis in the bacterial cell; the si…
Food interactions
None known
Human targets
None mapped
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Absorption
Half-life
1 to 3 hours
Protein binding
Pharmacokinetic data: DrugBank · CC BY-NC 4.0
Known interactions with other medicines. Always consult a healthcare professional.
Showing 50 of 56 interactions
How the body processes this drug — absorption, distribution, metabolism, and elimination
ATC J01XX04
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Linked compound data from DrugBank Open Data (CC BY-NC 4.0)
Spectinomycin
Additional database identifiers
Drugs Product Database (DPD)
11211
Drugs Product Database (DPD)
8567
ChemSpider
14785
PDB
SCM
ZINC
ZINC000053006806
GenBank Gene Database
V00355
GenBank Protein Database
43010
UniProt Accession
RS12_ECOLI
DrugBank citations
If you use DrugBank data in your research, please cite:
- DrugBank 6.02024Recommended citationKnox C., Wilson M., Klinger C.M., et alDrugBank 6.0: the DrugBank Knowledgebase for 2024Nucleic Acids Res. 2024 Jan 552(D1):D1265-D1275
- DrugBank 5.02018Wishart D.S., Feunang Y.D., Guo A.C., et alDrugBank 5.0: a major update to the DrugBank database for 2018Nucleic Acids Res. 2017 Nov 846(D1):D1074-D1082
- DrugBank 4.02014Law V., Knox C., Djoumbou Y., et alDrugBank 4.0: shedding new light on drug metabolismNucleic Acids Res. 2014 Jan 142(1):D1091-7
- DrugBank 3.02011Knox C., Law V., Jewison T., et alDrugBank 3.0: a comprehensive resource for 'omics' research on drugsNucleic Acids Res. 2011 Jan39(Database issue):D1035-41
- DrugBank 2.02008Wishart D.S., Knox C., Guo A.C., et alDrugBank: a knowledgebase for drugs, drug actions and drug targets.Nucleic Acids Research2008 Jan36(Database issue):D901-6
- DrugBank 1.02006Wishart D.S., Knox C., Guo A.C., et alDrugBank: a comprehensive resource for in silico drug discovery and exploration.Nucleic Acids Research2006 Jan 134(Database issue):D668-72